Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: An evidence-based review

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 1273-1282

  Mandernach, Molly W ^a   Beyth, Rebecca J ^a,b   Rajasekhar, Anita ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apixaban; New oral anticoagulant; Target specific oral anticoagulant; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ANDEXANET ALFA; APIXABAN; CIRAPARANTAG; ENOXAPARIN; PLACEBO; PROTHROMBIN COMPLEX;

BLEEDING; BRAIN HEMORRHAGE; CAUSE OF DEATH; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

EID: 84940107399     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S68010     Document Type: Review

References (48)

1. US Department of Health and Human Services. The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Washington, DC: US Department of Health and Human Services; 2008. Available from: http://www.surgeongeneral.gov/library/calls/index.html. Accessed January 30, 2015.
2. Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol. 2009;145(3):286–295.
3. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet. 2010;376:2032–2039.
4. Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy. 2009;29(8):943–953.
5. Kahn S, Lim W, Dunn A, et al. Prevention of VTE in nonsurgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e195S–e226S.
6. Bristol-Myers Squibb Company. Coumadin (Warfarin Sodium) Tablets for Oral Use [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf. Accessed January 30, 2015.
7. O’Reilly R, Rytand D. “Resistance” to warfarin due to unrecognized vitamin K supplementation. N Engl J Med. 1980;303:160–161.
8. Suttie JW, Mummah-Schendel LL, Shah DV, Lyle BJ, Gregor JL. Vitamin K deficiency from dietary vitamin K restriction in humans. Am J Clin Nutr. 1988;47:475–480.
9. Booth SL, Charnley JM, Sadowski JA, et al. Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with a constant vitamin K1 content. Thromb Haemost. 1997;77:504–509.
10. Wells PS, Holbrook AM, Crowther NR, Hirsh J. The interaction of warfarin with drugs and food: a critical review of the literature. Ann Intern Med. 1994;121:676–683.
11. Boehringer Ingelheim Pharmaceuticals, Inc. Pradaxa (Dabigatran Etexilate Mesylate) Capsules for Oral Use [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s024lbl.pdf. Accessed January 30, 2015.
12. Janssen Pharmaceuticals, Inc. Xarelto (Rivaroxaban) Tablets for Oral Use [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022406s012lbl.pdf. Accessed January 30, 2015.
13. Bristol-Myers Squibb Company. ELIQUIS (Apixaban) Tablets for Oral Use [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s024lbl.pdf. Accessed January 30, 2015.
14. Daiichi Sankyo Co. Savaysa (Edoxaban) Tablets for Oral Use [prescribing information]. Tokyo, Japan: Daiichi Sankyo Co., LTD; 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf. Accessed January 30, 2015.
15. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6:820–829.
16. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1–22.
17. Weitz J, Eikelboom J, Samama M. New antithrombotic drugs. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(Suppl):e120S–e151S.
18. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141 (2 suppl): e278S–e325S.
19. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594–604.
20. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2); a randomized double-blind trial. Lancet. 2010;375(9717):807–815.
21. Schulman S, Kearon C; on behalf of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemos. 2005;3:692–694.
22. Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomized trials. Thromb Haemost. 2011;105(2):245–253.
23. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM;ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010; 363(26):2487–2498.
24. Agnelli G, Buller HR, Cohen A, et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.
25. Agnelli G, Buller HR, Cohen A, et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708.
26. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2): 476–487.
27. Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost. 2013;110(2):283–294.
28. Sié P, Samama C, Godier A, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis. Arch Cardiovasc Dis. 2011;104(12):669–676.
29. Spyropoulos A, Douketis J. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120(15): 2954–2962.
30. Douketis J, Spyropoulos A, Spencer F, et al. Perioperative management of antithrombotic therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e326S–e3350S.
31. Nutescu EA. Oral anticoagulant therapies: balancing the risks. Am J Health Syst Pharm. 2013;70(10 Suppl):S3–S11.
32. Pathak R, Pandit A, Karmacharya P, et al. Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. Am J Cardiol. 2015;115:323–327.
33. Granger C, Alexander J, McMurray J, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11): 981–992.
34. Connolly S, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;354(9):806–817.
35. Lopez-Jimenez L, Montero M, Gonzalez-Fajardo JA, et al. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica. 2006;91:1046–1051.
36. Sardar P, Chatterjee S, Chaudhari S, Lip G. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014;62:857–864.
37. Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10(5):807–814.
38. Hankey GJ. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? Curr Cardiol Rep. 2014;16(5):480.
39. Touma L, Fillon K, Atallah R, et al. A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists. Am J Cardiology. 2015;115:533–541.
40. Hylek E, Held C, Alexander J, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin. J Am Coll Cardiol. 2014;63(20):2141–2147.
41. Pfizer Labs. Heparin Sodium Injection for Intravenous or Subcutaneous Use [prescribing information]. New York, NJ: Pfizer Labs; 2011. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201370s000lbl.pdf. Accessed January 30, 2015.
42. Siegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis. Epub 2015 Jan 14.
43. Perlstein I, Wang Z, Song Y, et al. Reversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in healthy subjects [abstract]. Blood. 2014;124(21):345.
44. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–451.
45. Crowther M, Gold A, Lu G et al. ANNEXA-A PART 2: A phase 3 randomized, double-blind, placebo-controlled trial demonstrating sustained reversal of apixaban-induced anticoagulation in older subjects by andexanet Alfa (PRT064445), a universal antidote for factor Xa (FXA) inhibitors. J Thromb Haemost. 2015;13 (Suppl. 2). Abstract LB004.
46. Laulicht B, Bakhru S, Lee C, et al. Small molecule antidote for anticoagulants [abstract]. Circulation. 2012;126:A11395.
47. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22): 2141–2142.
48. Revankar N, Patterson J, Kadambi A, et al. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. Postgrad Med. 2013;125(4):141–153.